Immunological and metabolic optimization of tumor neoantigen vaccines

References

1. 1.↵
   2. Katsikis PD,
   3. Ishii KJ,
   4. Schliehe C.

   Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024; 24: 213–27.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Stone JD,
   3. Harris DT,
   4. Kranz DM.

   TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol. 2015; 33: 16–22.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Huang D,
   3. Zhu X,
   4. Ye S,
   5. Zhang J,
   6. Liao J,
   7. Zhang N, et al.

   Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 2024; 625: 593–602.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Ely ZA,
   3. Kulstad ZJ,
   4. Gunaydin G,
   5. Addepalli S,
   6. Verzani EK,
   7. Casarrubios M, et al.

   Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science. 2025; 388: eadk3487.
5. 5.↵
   2. Bjerregaard A-M,
   3. Nielsen M,
   4. Jurtz V,
   5. Barra CM,
   6. Hadrup SR,
   7. Szallasi Z, et al.

   An analysis of natural T cell responses to predicted tumor neoepitopes. Front Immunol. 2017; 8: 1566.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Wells DK,
   3. van Buuren MM,
   4. Dang KK,
   5. Hubbard-Lucey VM,
   6. Sheehan KCF,
   7. Campbell KM, et al.

   Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020; 183: 818–34.e13.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Huber F,
   3. Arnaud M,
   4. Stevenson BJ,
   5. Michaux J,
   6. Benedetti F,
   7. Thevenet J, et al.

   A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2025; 43: 1360–72.

   OpenUrlPubMed
8. 8.↵
   2. Demmers LC,
   3. Kretzschmar K,
   4. Van Hoeck A,
   5. Bar-Epraïm YE,
   6. van den Toorn HWP,
   7. Koomen M, et al.

   Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat Commun. 2020; 11: 5338.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Wang J,
   3. Xie X,
   4. Jiang S,
   5. Lu L.

   Immunoengineered adjuvants for universal vaccines against respiratory viruses. Fundam Res. 2021; 1: 189–92.

   OpenUrlPubMed
10. 10.↵
    2. Wang X,
    3. Huang Z,
    4. Xing L,
    5. Shang L,
    6. Jiang J,
    7. Deng C, et al.

    STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature. 2025; 641: 202–10.

    OpenUrlPubMed
11. 11.↵
    2. Kon E,
    3. Ad-El N,
    4. Hazan-Halevy I,
    5. Stotsky-Oterin L,
    6. Peer D.

    Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023; 20: 739–54.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Wang J,
    3. Li P,
    4. Yu Y,
    5. Fu Y,
    6. Jiang H,
    7. Lu M, et al.

    Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science. 2020; 367: eaau0810.
13. 13.↵
    2. Li Y,
    3. Mo J,
    4. Liu J,
    5. Liang Y,
    6. Deng C,
    7. Huang Z, et al.

    A micro-electroporation/electrophoresis-based vaccine screening system reveals the impact of vaccination orders on cross-protective immunity. iScience. 2023; 26: 108086.
14. 14.↵
    2. Liu X,
    3. Jiang J,
    4. Liu J,
    5. Yang H,
    6. Huang Z,
    7. Deng C, et al.

    Nanoneedle array-electroporation facilitates intranuclear ribonucleoprotein delivery and high throughput gene editing. Adv Healthc Mater. 2024; 13: e2400645.
15. 15.↵
    2. Caron E,
    3. Vincent K,
    4. Fortier M-H,
    5. Laverdure J-P,
    6. Bramoullé A,
    7. Hardy M-P, et al.

    The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol. 2011; 7: 533.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    2. Valečka J,
    3. Almeida CR,
    4. Su B,
    5. Pierre P,
    6. Gatti E.

    Autophagy and MHC-restricted antigen presentation. Mol Immunol. 2018; 99: 163–70.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. Llibre A,
    3. Kucuk S,
    4. Gope A,
    5. Certo M,
    6. Mauro C.

    Lactate: a key regulator of the immune response. Immunity. 2025; 58: 535–54.

    OpenUrlCrossRefPubMed
18. 18.↵
    2. Giovanelli P,
    3. Sandoval TA,
    4. Cubillos-Ruiz JR.

    Dendritic cell metabolism and function in tumors. Trends Immunol. 2019; 40: 699–718.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Herber DL,
    3. Cao W,
    4. Nefedova Y,
    5. Novitskiy SV,
    6. Nagaraj S,
    7. Tyurin VA, et al.

    Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010; 16: 880–6.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Kaymak I,
    3. Luda KM,
    4. Duimstra LR,
    5. Ma EH,
    6. Longo J,
    7. Dahabieh MS, et al.

    Carbon source availability drives nutrient utilization in CD8+ T cells. Cell Metab. 2022; 34: 1298–311.e6.

    OpenUrlCrossRefPubMed